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ABSTRACT In myasthenia gravis an autoimmune re-
sponse against the nicotinic acetyicholine receptor (AChR)
occurs. The a subunit of the AChR contains both the epitope(s)
that dominates the antibody response (main immunogenic
region) and epitopes involved in T helper cell sensitization. In
this study, overlapping synthetic peptides corresponding to the
complete AChR a-subunit sequence were used to propagate
polyclonal AChR-specific T helper cell lines from four myas-
thenic patients of different HLA types. Response ofthe T helper
lines to the individual peptides was studied. Four immunodom-
inant sequence segments were identified-i.e., residues 48-67,
101-120, 304-322, and 419-437. These regions did not include
residues known to form the main immunogenic region or the
cholinergic binding site, and they frequently contained se-
quence motifs that have been proposed to be related to T-
epitope formation.
In the human disease myasthenia gravis (MG) the nicotinic
acetylcholine receptor (AChR) at the neuromuscularjunction
is the target of an autoimmune reaction (1-3). The AChR is
formed by four subunits (a, /3, y, and 8) (4). The anti-AChR
antibodies in MG patients are mostly against a small area of
the AChR a subunit, called the main immunogenic region
(5-7). AChR-specific T helper (TH) CD4' cells have been
demonstrated in MG patients (8-10), and these cells fre-
quently recognize the a subunit (11).
Unlike B cells, which recognize structural features of the
soluble, native form of protein antigens, TH cells recognize
denatured antigens in association with HLA class II mole-
cules on the surface of antigen-presenting cells (APC).
AChR-specific TH (CD4+) cells from the blood of MG pa-
tients recognize equally well native or fully denatured AChR
or the isolated, denatured a subunit (11). Therefore, synthetic
peptides corresponding to different subunits of the human
AChR, whose sequence is known, can be used to define the
epitopes recognized by the autoreactive, AChR-specific TH
cells. In previous studies, we demonstrated that AChR-
specific TH cells present in the blood of MG patients are
stimulated by a pool of synthetic peptides corresponding to
the complete sequence of the human a subunit (a-Pool) to an
extent that correlates well with the severity of myasthenic
symptoms (12) and that AChR-specific CD4' cell lines can be
propagated from the blood of myasthenic patients by stimu-
lation with the a-Pool (13). In the present study we have used
four anti-AChR CD41 T-cell polyclonal lines, propagated
from MG patients of different HLA type by the use of the
a-Pool, to systematically investigate the sequence segments
of the a subunit that form T epitopes.
MATERIALS AND METHODS
Patients. Anti-AChR CD4' T-cell polyclonal lines were prop-
agated from fourMG patients. Three patients (lines 1, 2, and 3)
had moderate generalized symptoms, one (line 4) was in clinical
remission. The HLA type of the patients, as determined by
standard microlymphotoxicity techniques (14) was as follows:
patient 1, A2,AW30/B13,B27/CW1/DR1,DR4/DQ1,DQ3;
patient 2, A2,A29/B7,BW44/DR2,DR7/DQ1,DQ2; patient
3, A1,A29/B8,BW44/DR3,DR7/DQ2,DQ2; patient 4, Al/
B7,BW44/DR2,DR4/DQ1,DQ3.
Peptide Synthesis and Characterization. Thirty-two pep-
tides, 14-20 residues long and corresponding to the complete
sequence of the human AChR a subunit (as reported in refs.
15 and 16, see Fig. 1), were synthesized by manual parallel
synthesis (19). The peptides overlapped each other by 4-8
residues to minimize the risk of missing epitopes "split"
between peptides. The purity of the synthetic peptides was
assessed by HPLC using a C18 column (Ultrasphere ODS)
and a gradient of acetonitrile in 0.1% trifluoroacetic acid
water, which consistently revealed one main peak of optical
density. The composition of the peptides, determined by
phenylthiocarbamoyl derivatization of the amino acids re-
leased by acid hydrolysis (20), yielded a satisfactory corre-
spondence between experimental and expected values for all
peptides. The sequence and purity ofsome randomly selected
peptides was further verified by gas-phase sequencing (Ap-
plied Biosystems); only the expected sequence was found.
Contaminating sequences (shorter homologous peptides
where one or more residues were randomly missing because
of incomplete coupling) were 5-15% of total signal.
Purification and Characterization of Torpedo AChR (TA-
ChR). Native membrane-bound TAChR was prepared from
Torpedo californica (21, 22). TAChR concentration was mea-
sured as 125I-labeled a-bungarotoxin (a-BGT) binding sites
using the disk assay of Schmidt and Raftery (23). Specific
activity of these preparations (expressed as nmol of 125I-a-
BGT binding sites per mg of protein) was 4-7 nmol/mg of
protein (maximum theoretical activity of pure AChR: 7.2
nmol/mg). a-BGT was purified from Bungarus multicinctus
venom (24) and radiolabeled with 1251I, as described in ref. 25.
Specific activity of 125I-a-BGT was determined as described
by Blanchard et al. (26).
Propagation of TH Cell Lines Specific for the AChR a
Subunit. The pool of synthetic peptides corresponding to the
complete sequence of the a subunit of the human AChR
(a-Pool) was used to propagate AChR-specific T-cell lines.
Abbreviations: a-BGT, a-bungarotoxin; 125I-a-BGT, radiolabeled
a-bungarotoxin; AChR, nicotinic acetylcholine receptor; TAChR,
Torpedo AChR; MG, myasthenia gravis; a-Pool, pool of synthetic
peptides corresponding to the complete sequence of the a subunit of
human muscle AChR; APC, antigen-presenting cells; PHA, phyto-
hemagglutinin; TH, T helper.
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FIG. 1. Synthetic peptides used in this study, aligned on the
sequence of human a subunit (from refs. 15 and 16). The segments
with high propensity to form amphipathic a-helices, proposed to be
related to T-epitope formation (17), are indicated in dotted boxes,
and those containing the T-epitope motif of Rothbard and Taylor (18)
are indicated in black boxes. Analysis of the a subunit sequence for
propensity to form amphipathic a-helices was done by J. A. Ber-
zofsky, J. Cornette, C. De Lisi, and H. Margalit, National Institutes
of Health.
Peripheral blood mononuclear cells (2-4 x 107) in RPMI 1640
medium (GIBCO) supplemented with 10o heat-inactivated
human serum, 2 mM L-glutamine, penicillin at 100 units/ml,
streptomycin at 50 kug/ml (tissue culture medium) containing
a final a-Pool concentration of each peptide at 1 Ag/ml were
seeded at a concentration of 1-2 x 106 cells per ml in T25
flasks (Costar) and cultivated for 1 week. The reactive
lymphoblasts were isolated on Percoll gradients (27), further
expanded in T-cell growth factor (Lymphocult, Biotest Di-
agnostics, Dreirich, F.R.G.) containing interleukin 2 at 10
units per ml, and enriched by approximately weekly stimu-
lation with the same amount of antigen plus irradiated (4000
rads; 1 rad = 0.01 Gy) autologous or HLA-DR-matched
peripheral blood mononuclear cells as antigen-presenting
cells (APC). The T-cell lines obtained were tested approxi-
mately every week for their ability to respond to the a-Pool
and to phytohemagglutin (PHA). The enrichment in a-Pool
reactivity was considered satisfactory when the response to
the a-Pool was comparable or higher than the response to
PHA, and this was achieved after 4-9 weeks of culture. The
phenotype of the T-cell lines was determined by fluores-
cence-activated cell sorting by using phycoerythrin-
conjugated Leu 2 (anti-CD8), Leu 3 (anti-CD4), and Leu 4
(anti-CD3) antibodies. Dilutions, washings, and incubations
were performed in phosphate-buffered saline at 40C.
Microproliferation Assay. The T-line cells (blasts) were
diluted to 2 x 105 cells per ml in tissue culture medium.
Autologous or HLA-DR-matched peripheral blood mononu-
clear cells, to be used as APC, were irradiated (4000 rads) and
diluted to 2 x 106 cells in tissue culture medium. The cells
were plated in triplicate in 96-round-bottom-well plates (100
A.l of blast cells and 100 Al ofAPC). The cells were stimulated
with a-Pool (0.05, 0.1, 0.5, 1, and 5 Ag/ml of each peptide),
or 1% PHA (Wellcome), or T-cell growth factor (Lympho-
cult, final concentration of interleukin 2, 10 units/ml) or
TAChR (20, 10, 5, and 2.5 Agg/ml), or each of the 32 peptides
present in the a-Pool (10 jig/ml). Triplicate wells with blasts
alone and three wells with APC alone were used as controls.
Three wells with blasts plus APC that did not receive any
stimulus and three wells with blasts plus APC plus a 19-
residue synthetic peptide unrelated to the human a subunit
indicated as E73 in Fig. 3 (residues 1-19 of the major intrinsic
protein of bovine lens) (10 Ag/ml) were used to determine the
basal growth rate (blanks). After 3 days the cultures were
treated for 16 hr with [3H]thymidine (1 dxCi per well, specific
activity 6.7 Ci/mmol; 1 Ci = 37 GBq, Amersham). The cells
were collected with a Skatron Titertek multiple harvester,
and the thymidine incorporated was measured in a liquid
scintillation counter.
RESULTS AND DISCUSSION
T-cell lines could be propagated, by cycles of stimulation
with a-Pool and interleukin 2, for several months. Their
phenotype was uniformly CD3', CD4', CD8-. The speci-
ficity for the a-Pool of the lines was tested by microprolif-
eration assay every week during their propagation. All the
lines responded vigorously to the a-Pool (Fig. 2). Three lines
were tested for cross-reactivity with native TAChR. Two of
them (lines 1 and 4) had a weak but consistent response to
TAChR (Fig. 2). Line 3 did not cross-react with TAChR.
Because the sequences of TAChR and human AChR a
subunits are only 81% identical (11, 15, 16), a limited cross-
reactivity of our lines should be expected. In most experi-
ments the anti-AChR T-cell lines increased their proliferation
rate when autologous or HLA-DR-matched irradiated APC
were added, in the absence of AChR antigens. This may be
from reaction to the autologous HLA-DR molecules, as
described for human and rodent T cells (28-30) and has been
described in more detail in a previous report (13).
Because in vitro immunization against the a-Pool cannot be
excluded and to investigate whether anti-AChR T cells are
present in the blood of normal subjects, we attempted prop-
agation of T-cell lines from four healthy subjects using the
same procedure as for the myasthenic patients, or by cycles
of stimulation with APC alone followed by expansion with
interleukin 2. Control T cells could not be propagated for
more than two stimulation cycles. The cells obtained re-
sponded strongly to APC, but they never responded to the
a-Pool or to TAChR.
Reactivity of the anti-AChR CD4+ T-cell lines from my-
asthenic patients to the individual peptides was periodically
investigated by microproliferation assays. Fig. 3 reports the
results of different tests, carried out at 1- to 2-week intervals
during propagation of the lines. Basal rate of cell division
varied with different lines and even for the same cell line
because it depends on both the anti-DR component of the cell
line and the degree to which the T cells had reverted to the
resting state at the time of the test. Some peptides were
clearly and consistently recognized. Line 1 in all tests re-
sponded to peptides Ha48-67, HalO1-120, and Ha304-322.
Line 2 clearly recognized peptides Ha320-337 and Ha419-
437. A significant, although sometimes smaller, response to
peptides Ha48-67, HalO1-120, and Ha304-322 was detected
in at least one experiment. Line 3 recognized consistently and
strongly the two overlapping peptides Ha32-51, Ha48-67,
and peptide Ha304-322. In one experiment peptide Ha419-
437 was also recognized. Line 4 strongly recognized peptide
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FIG. 2. Response to different stimuli of the CD4+ T-cell lines propagated from MG patients, measured by microproliferation assay.
Incorporation of [3H]thymidine by T cells is shown in the presence of APCs only (B+APC) or increased concentrations of a-Pool or purified
membrane-bound TAChR. Positive controls were the (3H]thymidine incorporation induced by PHA at 10 ,g/ml or interleukin 2 (IL2) at 10
units/ml. All lines responded vigorously to the a-Pool. Lines 1 and 4 cross-reacted with TAChR, whereas line 3 did not. Line 2 was not tested
for cross-reactivity with TAChR.
Ha304-322. Peptides Ha48-67, HalO1-120, Hal91-207, and
Ha419-437 were frequently recognized-particularly at the
beginning of the propagation of the CD4' T-cell line. At later
stages of propagation these peptides were less frequently
recognized, possibly because of clonal loss. CD4' T cells,
which could be propagated for short times from healthy
controls by stimulation with APC and a-Pool or APC alone,
were tested for reactivity to the individual peptides. No
response was detected.
Fig. 4 summarizes the sequence segments recognized by
the four CD4' lines. Immunodominant regions exist, recog-
nized by the autoreactive anti-AChR CD4' cells of most or
all myasthenic patients, irrespective of their HLA type.
Because T epitopes can be as small as seven residues (31),
these regions, which are 20 or more residues long, could
accommodate several overlapping T epitopes, recognized in
association with the same or different restriction elements, as
it occurs in other systems (32-35). The TH immunodominance
of these regions may be from easier cleavage and processing
and/or better ability of the excised segments to fold into a
secondary structure agreeable with DR molecule binding.
Alternatively, one or more of these sequence segments may
contain a single immunodominant T epitope, recognized
within several or any major histocompatibility complex class
II haplotype, as described for epitopes on the human immu-
nodeficiency virus, Plasmodiumfalciparum, and influenza A
virus (36, 37). Such an immunodominant epitope would be
the TH-cell counterpart of the main immunogenic region,
which dominates the antibody response to the AChR, irre-
spective of the HLA haplotype of the patients.
Other patients may exist on the a subunit, undetected in
this study because of (i) clonal loss of the relevant T cells, (ii)
"breaking" of the epitope between two peptides, and/or (iii)
presence of sequence segments flanking the T epitope exert-
ing negative effects on recognition of the epitope by T-cell
clones (38).
DeLisi and Berzofsky (17) proposed that T epitopes are
formed by sequence segments that can form amphipathic
a-helices. Segments of the human a subunit with highest
propensity to form amphipathic helices are indicated in Fig.
1 (dotted boxes), and they include two immunodominant
peptides. Rothbard and Taylor (18) suggested that T epitopes
contain a sequence motif composed ofamino acid residues in
the following sequence: (i) charged or glycine, (ii) hydropho-
bic, (iii) hydrophobic, (iv) charged, polar, or hydrophobic, (v)
charged or polar, if residue iv is hydrophobic. The segments
of the a-subunit sequence containing this motif are indicated
in Fig. 1 (black boxes); they comprise three immunodominant
peptides. Interestingly, the epitope most strongly recognized
by all patients is within the sequence 304-337, which is
predicted to contain the longest anphipathic a-helical seg-
ment and also contains two nonoverlapping Rothbard and
Taylor motifs. Only one stimulatory peptide did not corre-
spond to any of the predicted T-cell epitopes.
Harcourt and colleagues (39) tested blood lymphocytes
from myasthenic patients and healthy controls with synthetic
sequence segments of the human a subunit. The only specific
response of the myasthenic subjects was to a peptide a257-
269. The responder patients had different HLA haplotypes,
including HLA-DR 2,7 and 3,7 like our patients 2 and 3,
whose TH line did not respond to peptides Ha230-249 and
Ha246-264, which overlap peptide a257-269 of Harcourt et
al. Possible explanations of this discrepancy include (i) the
epitope may be "broken" between the two peptides used
here, and the corresponding TH cells are lost in the propa-
gation procedure; (ii) patients of the same DR haplotype may
have different abilities to recognize a given TH epitope
because of the influence of non-major histocompatibility
complex factors on the expression of TH responses (34, 35).
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FIG. 3. Response of the anti-AChR CD4+ T-cell lines from MG patients to the individual synthetic peptides forming the a-Pool. The first
test was carried out after a satisfactory enrichment in a-Pool-specific T cells was reached, as indicated by reactivity to the a-Pool as high or
higher than the response to the unspecific stimulant PHA. A, B, C, andD refer to successive tests done at 1- to 2-week intervals. Asterisks indicate
responses significantly higher than the unstimulated proliferative rate (*, P < 0.01; **, P < 0.05; ***, P < 0.010; ****, P < 0.025).
In another study (40) three TH cell lines from different MG
patients (HLA-DR 3,4; 3,4; and 3,11 respectively), propa-
gated by the use of a fusion protein corresponding to a large
part of mouse AChR a subunit, recognized a major epitope
within residues 85-142. If that epitope were restricted by the
DR 4 and DR 11 molecules, it could be within the sequence
Ha101-120 recognized by our lines 1, 2, and 4.
All stimulatory peptides were within sequence segments





extracellular (sequences 62-67, 101-120, 191-207, and pos-
sibly 419-437) or cytoplasmic (sequence 304-337). None of
the T-immunodominant regions overlaps the main immuno-
genic region, which is between residues 67 and 76 of the
human a subunit (6), although one imnmunodominant region
ends at residue 67. A constituent loop of the cholinergic
binding site, against which antibodies can be produced in
myasthenic patients, is within the sequence a184-198 (42-








#1 (DR 1J4) - -
#2 (DR 2,7) Lz m '\
#3 (DR 3,7)
#4 (DR 2,4) L_, _
FIG. 4. Sequence segments recognized by the four T-cell lines and their HLA-DR haplotypes. Peptides that elicited a strong response are
indicated as dark stippled segments, peptides that elicited an intermediate response are indicated as more closely hatched segments, and peptides
that elicited a low:but significant response are indicated as less closely hatched segments.
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However the actual T epitope may not overlap the choliner-
gic binding site, as suggested by the presence of the motif of
Rothbard and Taylor at residues 204-208.
Although the TH response against AChR in MG is poly-
clonal, limited defined regions of the a subunit sequence
seem to be involved in the formation ofthe TH epitopes in this
autoimmune response. A similar situation occurs in experi-
mental autoimmune encephalomyelitis, where CD4' T cells
of different mice strains respond to "nested" epitopes within
immunodominant regions (46). In experimental autoimmune
encephalomyelitis, epitopes that stimulate pathogenic CD4'
T clones were identified and "T-cell vaccination" procedures
were developed, by which immunization of animals against
inactivated autoimmune CD4' cells or against unique se-
quence segments of their T-cell receptor protected from the
disease and ameliorated existing symptoms (47-51). Propa-
gation of human anti-AChR CD4' T-cell lines and identifi-
cation of the TH epitopes recognized by these autoreactive TH
cells will be useful steps toward development of similar
therapeutic strategies in MG.
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